Short-course isoniazid and rifampin compared with isoniazid for latent tuberculosis infection: A randomized clinical trial;Pauta corta de isoniazida y rifampicina comparada con isoniazida para la infección latente de tuberculosis. Ensayo clínico aleatorizado

Enfermedades Infecciosas y Microbiologia Clinica

Volumn 25, Issue 5, 2007, Pages 300-304

  Geijo, María Paloma ^a   Herranz, Carmen Rosa ^a   Vaño, David ^a   García, Ángel Jesús ^b   García, Montserrat ^a   Dimas, José Francisco ^a  

^a HOSPITAL VIRGEN DE LA LUZ   (Spain)

^b Centro de Salud Cuenca I   (Spain)

Author keywords

Clinical trial; Isoniazid; Latent tuberculosis infection; Rifampin

Indexed keywords

ISONIAZID; RIFAMPICIN;

ADULT; ARTHRALGIA; ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; PATIENT COMPLIANCE; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SKIN TOXICITY; THROMBOCYTOPENIA; TUBERCULIN TEST; TUBERCULOSIS; UNSPECIFIED SIDE EFFECT;

EID: 34547631812     PISSN: 0213005X     EISSN: 15781852     Source Type: Journal    
DOI: 10.1157/13102264     Document Type: Article

References (26)

1. Moreno S, Cobo J. Las múltiples caras del control de la tuberculosis. Enferm Infecc Microbiol Clin. 2003;21:279-80.
2. KHan K, Muennig P, Behta M, Graff J. Global drug-resistance patterns and the management of latent tuberculosis infection in immigrants to the United States. N Engl J Med. 2002;347:1850-9.
3. McNicol MW, Thompson H, Riordan JF, Forde E, Allen CJ. Antituberculous chemoprophylaxis with isoniazid-rifampin. Thorax. 1984;39:223-4.
4. Girling DJ. Double-blind placebo-controlled clinical trial of three antituberculosis chemoprophylaxis regimens in patients with silicosis in Hong Kong. Am Rev Respir Dis. 1992;145:36-41.
5. British Thoracic Society Chemotherapy and management of tuberculosis in the United Kingdom: recommendations of the Joint Tuberculosis Committee of the British Thoracic Society. Thorax. 1990;45:403-8.
6. Grupo de Trabajo del PMIT. Incidencia de la tuberculosis en España: Resultados del Proyecto Multicéntrico de Investigación en Tuberculosis (PMIT). Med Clin (Barc). 2000;114:530-7.
7. Centers for Disease Control and Prevention (CDC). The use of preventive therapy for tuberculosis infection in the United States. Recommendations of the Advisory Committee for Elimination of Tuberculosis. MMWR. 1990;39 Suppl RR-8:9-12.
8. Bran C, Gómez i Prat J, Cayla JA, García de Olalla P. Factors associated with latent tuberculous infection in immigrants less than 35 years old. Enferm Infecc Microbiol Clin. 2006;24:322-5.
9. Grupo de trabajo del área TIR de SEPAR. Normativa sobre la prevención de la tuberculosis. Arch Bronconeumol. 2002;38:441-51.
10. Aguado JM, Rufi G, García Rodríguez JA, Solera J. Protocolos clínicos SEIMC. Tuberculosis. Profilaxis de Tuberculosis. Edición electrónica. Octubre 2003; 14-33. Disponible en: http://www.seimc.org/protocolos/clinicos/index.htm
11. Centers for Disease Control and Prevention (CDC). Targeted tuberculin testing and treatment of latent tuberculosis infection. MMWR. 2000;49(RR-6):1-51.
12. Centers for Disease Control and Prevention (CDC). Update: adverse event data and revised American Thoracic Society/CDC recommendations against the use of rifampin and pyrazinamide for treatment of latent tuberculosis infection United States, 2003. MMWR. Morb Mortal Wkly Rep. 2003;52:7359.
13. Yuan L, Richardson E, Kendall PRW. Evaluation of a tuberculosis screening program for high-risk student in Toronto schools. Can Med Assoc J. 1995;153:925-32.
14. Martínez Alfaro E, Solera J, Cuenca D, Castillejos ML, Espinosa A, Sáez L. Cumplimentación, tolerancia y eficacia de una pauta corta de quimioprofilaxis para el tratamiento de la tuberculosis. Med Clin (Barc). 1998;111:401-4.
15. Portilla J, Jordá P, Esteban J, Sánchez-Payá J, Merino E, Boixe V; y Grupo de Estudio Protocolo-INH. Tratamiento directamente observado de la infección tuberculosa latente: estudio comparativo de dos pautas con isoniazida. Enferm Infecc Microbiol Clin. 2003;21:293-5.
16. Malcolm AS, Burk RF, Des Prez RM. Toxic hepatitis with isoniacid and rifampin. A meta-analysis. Chest. 1991;99:465-71.
17. Jasmer RM, Saukkonen JJ, Blumberg HM, Daley CL, Bernardo J, Vittinghoff E, et al, for the Short-Course Rifampin and Pyrazinamide for Tuberculosis Infection (SCRIPT) Study Investigators. Short-Course Rifampin and Pyrazinamide Compared with Isoniazid for Latent Tuberculosis Infection: A Multicenter Clinical Trial. Ann Intern Med. 2002;137:640-7.
18. Gordin F, Chaisson RE, Matts JP, Miller C, De Lourdes García M, Hafner R, et al. Rifampin and pyrazinamide vs isoniazid for prevention of tuberculosis in HIV-infected persons: an international randomized trial. Terry Beirn Community Programs for Clinical Research on AIDS, the Adult AIDS Clinical Trials Group, the Pan American Health Organization, and the Centers for Disease Control and Prevention Study Group. JAMA. 2000;283:1445-50.
19. Rivero A, López-Cortés L, Castillo R, Lozano F, García MA, Díez F, et al. Ensayo clínico aleatorizado de tres pautas de quimioprofilaxis para prevenir la tuberculosis en pacientes infectados por el VIH con anergia cutánea. Enf Infec Microbiol Clin. 2003;21:287-92.
20. Martínez Alfaro E, Cuadra F, Solera J, Maciá MA, Geijo P, Sánchez Martínez PA, et al, y miembros del grupo GECMEI. Evaluación de dos pautas de quimioprofilaxis tuberculosa en pacientes infectados por el VIH. Med Clin (Barc). 2000;115:161-5.
21. Ridzon R, Meador J, Maxwell R, Higgins K, Weismuller P, Onorato IM. Asymptomatic hepatitis in persons who received alternative preventive therapy with pyrazinamide and ofloxacin. Clin Infect Dis. 1997;24:1264-5.
22. Geijo MP, Martínez Medina C, Rosa C, Ruiz Ribó MD. Riesgo-beneficio del tratamiento de tuberculosis, en un hospital provincial con una sensibilidad alta de la baciloscopia. An Med Intern. 1999;16:59-64.
23. Van Zyl S, Marais BJ, Hesseling AC, Gie RP, Beyers N, Schaaf HS. Adherence to anti-tuberculosis chemoprophylaxis and treatment in children. Int J Tuberc Lung Dis. 2006;10:13-8.
24. Tortajada C, Martínez J, Sánchez F, Jiménez A, De Souza M, Balagué M, et al. Estudio comparativo de isoniazida frente a una pauta corta de rifampicina y pirazinamida para el tratamiento de la infección tuberculosa latente. Enf Emerg. 2002;4:186-226.
25. Vikrant S, Agarwal SK, Gupta S, Bhowmik D, Tiwari SC, Dash SC, et al. Prospective randomized control trial of isoniazid chemoprophylaxis during renal replacement therapy. Transpl Infect Dis. 2005;7:99-108.
26. Grant AD, Charalambous S, Fielding KL, Day JH, Corbett EL, Chaisson RE, et al. Effect of routine isoniazid preventive therapy on tuberculosis incidence among HIV-infected men in South Africa: a novel randomized incremental recruitment study. JAMA. 2005;293:2719-25.